Dr. Oussaima Eldbouni
Scope of Practice
- Adult Immunization program
- Infectious Diseases specialist
- Management of complicated infections
- Management of nosocomial infections
- Outpatients, In patients with acute and chronic infections ability to diagnose and treat
- Prevention Diagnosis and management of Diseases caused by viral bacterial or parasitic infections
- Travel medicine and Pre-travel guidance for infectious diseases
Highlights
Academic Achievements
7
Publications
21
Conferences
Community Outreach Activities/Achievements
- Director of vaccination center for COVID 19 at RHUH
- Member of Leishmania program (at RHUH with Lebanese MOPH) treating and diagnosis
Health Care Profession Achievements
- +1Years6 of Experience
Experience & Education
- Infectious diseases Specialist Consultant
- Program Director of Internal Medicine Department, Rafik Hariri University Hospital
- Research fellowship in HIV, Hôpital Cochin, Paris, France
- Postgraduate diploma in Infection Control, Université Paris VII
- Subspecialty training in HIV (Infectious diseases), Hôpital Saint Joseph, Paris, France
- Post graduate diploma in Management of HIV patient, Université de Paris VII
- AFSA (Attestation de Formation Spécialisée Approfondie) en Infectiologie, Hôpital Saint Joseph, Paris, France
- Post graduate diploma in pathophysiology and therapeutics in infectious diseases, Université de Paris V
- AFS (Attestation de formation Spécialisée) en Infectiologie
- Fellowship-Infectious diseases, American University of Beirut, Lebanon
- Fellowship -Internal Medicine, Lebanese university, Beirut, Lebanon
- MD, 2000 Lebanese University, Beirut, Lebanon
Certifications
- Member of the LSID (Lebanese society of infectious diseases)
- Member of the ASM (American society for microbiology)
- Member of FIDSA (member of IDSA)
Publications
- Dipeptidyl peptidase III as a DNA marker to investigate epidemiology and taxonomy of Old World Leishmania species PLoS Negl Trop Dis 2021 Jul 26;15(7):e0009530. doi: 10.1371/journal.pntd.0009530. eCollection 2021 Jul.
- Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). Salmon-Ceron D, Cohen J, Winnock M, Roux P, Sadr FB, Rosenthal E, Martin IP, Loko MA, Mora M, Sogni P, Spire B, Dabis F, Carrieri MP; HEPAVIH group. BMC Health Serv Res. 2012 Mar 12;12:59
- Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S, Bani-Sadr F, Izopet J, Garraffo R, Peytavin G; ANRS CO-13 HEPAVIH Study Group. AIDS. 2012 Nov 13;26(17):2193-9
- Kamel Mohammedi, Ronan Roussel, Oussaima El Dbouni, Louis Potier, Claire Fieschi, Emilie Capel, Corinne Vigouroux, Martine CaronDebarle, Jacqueline Capeau, Michel Marre. Type B insulin resistance syndrome associated with an immune reconstitution inflammatory syndrome in an HIV-infected woman. J Clin Endocrinol Metab. 2011 Apr; 96(4):E653-7. Epub 2011 Jan 26.
- Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008. Michel L, Villes V, Dabis F, Spire B, Winnock M, Loko MA, Poizot-Martin I, Valantin MA, Bonnard P, Salmon-Céron D, Carrieri MP; ANRS Co13 HEPAVIH Study Group. J Viral Hepat. 2010 Sep; 17 (9): 650-60